Bausch + Lomb Corporation Stock

Equities

BLCO

CA0717051076

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-05-22 pm EDT 5-day change 1st Jan Change
14.7 USD +0.75% Intraday chart for Bausch + Lomb Corporation -1.93% -13.83%
Sales 2024 * 4.66B Sales 2025 * 4.94B Capitalization 5.17B
Net income 2024 * -236M Net income 2025 * -61M EV / Sales 2024 * 1.99 x
Net Debt 2024 * 4.12B Net Debt 2025 * 3.8B EV / Sales 2025 * 1.81 x
P/E ratio 2024 *
-24.8 x
P/E ratio 2025 *
-109 x
Employees 13,300
Yield 2024 *
-
Yield 2025 *
-
Free-Float 11.15%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.75%
1 week-1.93%
Current month+1.10%
1 month+0.41%
3 months-15.13%
6 months-3.67%
Current year-13.83%
More quotes
1 week
14.45
Extreme 14.45
15.27
1 month
13.16
Extreme 13.16
15.49
Current year
13.16
Extreme 13.16
17.70
1 year
13.16
Extreme 13.16
21.95
3 years
12.20
Extreme 12.2
21.95
5 years
12.20
Extreme 12.2
21.95
10 years
12.20
Extreme 12.2
21.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 23-03-05
Director of Finance/CFO 51 21-12-31
Chief Tech/Sci/R&D Officer 57 22-01-30
Members of the board TitleAgeSince
Chief Executive Officer 56 23-03-05
Director/Board Member 68 -
Director/Board Member 44 22-06-20
More insiders
Date Price Change Volume
24-05-22 14.7 +0.75% 468,044
24-05-21 14.59 +0.55% 147,311
24-05-20 14.51 -0.96% 221,521
24-05-17 14.65 -3.87% 632,656
24-05-16 15.24 +1.67% 284,953

Delayed Quote Nyse, May 22, 2024 at 04:00 pm EDT

More quotes
Bausch + Lomb Corporation is a Canada-based global eye health company. The Company’s Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Company’s Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Company’s brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
14.7 USD
Average target price
18.71 USD
Spread / Average Target
+27.31%
Consensus